Clinical Trial Update: Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2a trial of desipramine in small cell lung cancer and other high-grade neuroendocrine tumors was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors
• Small Cell Lung Cancer

Drugs mentioned

• Desipramine (desipramine)

Snippet

Sponsor: Joel Neal | Conditions: Small Cell Lung Cancer (SCLC), Neuroendocrine Tumors | Phase 2 | Status: TERMINATED | Results posted: 2017-04-17